APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cystic Fibrosis (CF) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cystic Fibrosis (CF) Therapeutics Market Outlook and Growth Opportunities 2026

21 December 2025194 pages

Choose your research edition.

Industry ResearchCystic Fibrosis (CF) Therapeutics Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Cystic Fibrosis (CF) Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Cystic Fibrosis (CF) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cystic Fibrosis (CF) Therapeutics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Cystic Fibrosis (CF) Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Cystic Fibrosis (CF) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cystic Fibrosis (CF) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cystic Fibrosis (CF) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cystic Fibrosis (CF) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cystic Fibrosis (CF) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cystic Fibrosis (CF) Therapeutics market include Teva Pharmaceutical Industries Ltd, Novartis AG, Merck & Co., Gilead, AbbVie,, AstraZeneca, Vertex Pharmaceuticalsorporated, F. Hoffmann-La Roche Ltd and ALLERGAN, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Cystic Fibrosis (CF) Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cystic Fibrosis (CF) Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cystic Fibrosis (CF) Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Cystic Fibrosis (CF) Therapeutics market.

Cystic Fibrosis (CF) Therapeutics Segment by Company

Teva Pharmaceutical Industries Ltd

Novartis AG

Merck & Co.

Gilead

AbbVie,

AstraZeneca

Vertex Pharmaceuticalsorporated

F. Hoffmann-La Roche Ltd

ALLERGAN

Alcresta

Alaxia

AIT (Advanced Inhalation Therapies)

Cystic Fibrosis (CF) Therapeutics Segment by Type

Bronchodilators

Mucolytics

Pancreatic enzyme supplements

CFTR modulators

Cystic Fibrosis (CF) Therapeutics Segment by Application

Oral drugs

Inhaled drugs

Cystic Fibrosis (CF) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Cystic Fibrosis (CF) Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Cystic Fibrosis (CF) Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Cystic Fibrosis (CF) Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Cystic Fibrosis (CF) Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cystic Fibrosis (CF) Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Cystic Fibrosis (CF) Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cystic Fibrosis (CF) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cystic Fibrosis (CF) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cystic Fibrosis (CF) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cystic Fibrosis (CF) Therapeutics industry.

Chapter 3: Detailed analysis of Cystic Fibrosis (CF) Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Cystic Fibrosis (CF) Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Cystic Fibrosis (CF) Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cystic Fibrosis (CF) Therapeutics Industry Trends Table 2. Cystic Fibrosis (CF) Therapeutics Industry Drivers Table 3. Cystic Fibrosis (CF) Therapeutics Industry Opportunities and Challenges Table 4. Cystic Fibrosis (CF) Therapeutics Industry Restraints Table 5. Global Cystic Fibrosis (CF) Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cystic Fibrosis (CF) Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Cystic Fibrosis (CF) Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Cystic Fibrosis (CF) Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Cystic Fibrosis (CF) Therapeutics Company, Product Type & Application Table 10. Global Cystic Fibrosis (CF) Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Cystic Fibrosis (CF) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bronchodilators Table 15. Significant Companies of Mucolytics Table 16. Significant Companies of Pancreatic enzyme supplements Table 17. Significant Companies of CFTR modulators Table 18. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type (2021-2026) Table 22. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Oral drugs Table 24. Significant Companies of Inhaled drugs Table 25. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application (2021-2026) Table 29. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application (2027-2032) Table 30. Global Cystic Fibrosis (CF) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Region (2021-2026) Table 33. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Region (2027-2032) Table 35. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Cystic Fibrosis (CF) Therapeutics Sales Value Market Share by Country (2021-2026) Table 38. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Cystic Fibrosis (CF) Therapeutics Sales Value Market Share by Country (2027-2032) Table 40. Teva Pharmaceutical Industries Ltd Company Information Table 41. Teva Pharmaceutical Industries Ltd Business Overview Table 42. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 44. Teva Pharmaceutical Industries Ltd Recent Development Table 45. Novartis AG Company Information Table 46. Novartis AG Business Overview Table 47. Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Novartis AG Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 49. Novartis AG Recent Development Table 50. Merck & Co. Company Information Table 51. Merck & Co. Business Overview Table 52. Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 54. Merck & Co. Recent Development Table 55. Gilead Company Information Table 56. Gilead Business Overview Table 57. Gilead Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Gilead Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 59. Gilead Recent Development Table 60. AbbVie, Company Information Table 61. AbbVie, Business Overview Table 62. AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. AbbVie, Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 64. AbbVie, Recent Development Table 65. AstraZeneca Company Information Table 66. AstraZeneca Business Overview Table 67. AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 69. AstraZeneca Recent Development Table 70. Vertex Pharmaceuticalsorporated Company Information Table 71. Vertex Pharmaceuticalsorporated Business Overview Table 72. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 74. Vertex Pharmaceuticalsorporated Recent Development Table 75. F. Hoffmann-La Roche Ltd Company Information Table 76. F. Hoffmann-La Roche Ltd Business Overview Table 77. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 79. F. Hoffmann-La Roche Ltd Recent Development Table 80. ALLERGAN Company Information Table 81. ALLERGAN Business Overview Table 82. ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 84. ALLERGAN Recent Development Table 85. Alcresta Company Information Table 86. Alcresta Business Overview Table 87. Alcresta Cystic Fibrosis (CF) Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Alcresta Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 89. Alcresta Recent Development Table 90. Alaxia Company Information Table 91. Alaxia Business Overview Table 92. Alaxia Cystic Fibrosis (CF) Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Alaxia Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 94. Alaxia Recent Development Table 95. AIT (Advanced Inhalation Therapies) Company Information Table 96. AIT (Advanced Inhalation Therapies) Business Overview Table 97. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Portfolio Table 99. AIT (Advanced Inhalation Therapies) Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Cystic Fibrosis (CF) Therapeutics Product Image Figure 2. Global Cystic Fibrosis (CF) Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Cystic Fibrosis (CF) Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bronchodilators Image Figure 8. Mucolytics Image Figure 9. Pancreatic enzyme supplements Image Figure 10. CFTR modulators Image Figure 11. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type (2021-2032) Figure 14. Oral drugs Image Figure 15. Inhaled drugs Image Figure 16. Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application (2021-2032) Figure 19. Global Cystic Fibrosis (CF) Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Bronchodilators
  • Mucolytics
  • Pancreatic enzyme supplements
  • CFTR modulators
Applications
  • Oral drugs
  • Inhaled drugs
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • Merck & Co.
  • Gilead
  • AbbVie,
  • AstraZeneca
  • Vertex Pharmaceuticalsorporated
  • F. Hoffmann-La Roche Ltd
  • ALLERGAN
  • Alcresta
  • Alaxia
  • AIT (Advanced Inhalation Therapies)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Cystic Fibrosis (CF) Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Cystic Fibrosis (CF) Therapeutics Market Dynamics
  1. 2.1 Cystic Fibrosis (CF) Therapeutics Industry Trends
  2. 2.2 Cystic Fibrosis (CF) Therapeutics Industry Drivers
  3. 2.3 Cystic Fibrosis (CF) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Cystic Fibrosis (CF) Therapeutics Industry Restraints
3 Cystic Fibrosis (CF) Therapeutics Market by Company
  1. 3.1 Global Cystic Fibrosis (CF) Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Cystic Fibrosis (CF) Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Cystic Fibrosis (CF) Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Cystic Fibrosis (CF) Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Cystic Fibrosis (CF) Therapeutics Company Product Type and Application
  6. 3.6 Global Cystic Fibrosis (CF) Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Cystic Fibrosis (CF) Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Cystic Fibrosis (CF) Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Cystic Fibrosis (CF) Therapeutics Market by Type
  1. 4.1 Cystic Fibrosis (CF) Therapeutics Type Introduction
  2. 4.1.1 Bronchodilators
  3. 4.1.2 Mucolytics
  4. 4.1.3 Pancreatic enzyme supplements
  5. 4.1.4 CFTR modulators
  6. 4.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type
  7. 4.2.1 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type (2021-2032)
5 Cystic Fibrosis (CF) Therapeutics Market by Application
  1. 5.1 Cystic Fibrosis (CF) Therapeutics Application Introduction
  2. 5.1.1 Oral drugs
  3. 5.1.2 Inhaled drugs
  4. 5.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application
  5. 5.2.1 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application (2021-2032)
6 Cystic Fibrosis (CF) Therapeutics Regional Value Analysis
  1. 6.1 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Cystic Fibrosis (CF) Therapeutics Country-level Value Analysis
  1. 7.1 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Cystic Fibrosis (CF) Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Cystic Fibrosis (CF) Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Cystic Fibrosis (CF) Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Cystic Fibrosis (CF) Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Gilead
  20. 8.4.1 Gilead Company Information
  21. 8.4.2 Gilead Business Overview
  22. 8.4.3 Gilead Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gilead Cystic Fibrosis (CF) Therapeutics Product Portfolio
  24. 8.4.5 Gilead Recent Developments
  25. 8.5 AbbVie,
  26. 8.5.1 AbbVie, Company Information
  27. 8.5.2 AbbVie, Business Overview
  28. 8.5.3 AbbVie, Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Product Portfolio
  30. 8.5.5 AbbVie, Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Vertex Pharmaceuticalsorporated
  38. 8.7.1 Vertex Pharmaceuticalsorporated Company Information
  39. 8.7.2 Vertex Pharmaceuticalsorporated Business Overview
  40. 8.7.3 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Portfolio
  42. 8.7.5 Vertex Pharmaceuticalsorporated Recent Developments
  43. 8.8 F. Hoffmann-La Roche Ltd
  44. 8.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 8.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 8.9 ALLERGAN
  50. 8.9.1 ALLERGAN Company Information
  51. 8.9.2 ALLERGAN Business Overview
  52. 8.9.3 ALLERGAN Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Portfolio
  54. 8.9.5 ALLERGAN Recent Developments
  55. 8.10 Alcresta
  56. 8.10.1 Alcresta Company Information
  57. 8.10.2 Alcresta Business Overview
  58. 8.10.3 Alcresta Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alcresta Cystic Fibrosis (CF) Therapeutics Product Portfolio
  60. 8.10.5 Alcresta Recent Developments
  61. 8.11 Alaxia
  62. 8.11.1 Alaxia Company Information
  63. 8.11.2 Alaxia Business Overview
  64. 8.11.3 Alaxia Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Alaxia Cystic Fibrosis (CF) Therapeutics Product Portfolio
  66. 8.11.5 Alaxia Recent Developments
  67. 8.12 AIT (Advanced Inhalation Therapies)
  68. 8.12.1 AIT (Advanced Inhalation Therapies) Company Information
  69. 8.12.2 AIT (Advanced Inhalation Therapies) Business Overview
  70. 8.12.3 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Portfolio
  72. 8.12.5 AIT (Advanced Inhalation Therapies) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst